Related references
Note: Only part of the references are listed.The Cost-effectiveness of Biological Therapy Cycles in the Management of Crohn's Disease
Kristian Bolin et al.
JOURNAL OF CROHNS & COLITIS (2019)
De-escalation of immunomodulator and biological therapy in inflammatory bowel disease
Thomas P Chapman et al.
Lancet Gastroenterology & Hepatology (2019)
Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease
Floris Imhann et al.
GUT (2018)
Stopping Biologics in IBD-What Is the Evidence?
Edouard Louis
INFLAMMATORY BOWEL DISEASES (2018)
Practical guidance on the use of faecal calprotectin
Matthew J. Brookes et al.
FRONTLINE GASTROENTEROLOGY (2018)
Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease
Anthony Buisson et al.
INFLAMMATORY BOWEL DISEASES (2017)
Potential roles of neutrophils in regulating intestinal mucosal inflammation of inflammatory bowel disease
Guang Xi Zhou et al.
JOURNAL OF DIGESTIVE DISEASES (2017)
How to predict clinical relapse in inflammatory bowel disease patients
Elisa Liverani et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease
Joana Torres et al.
GASTROENTEROLOGY (2015)
864 Close Monitoring of CRP and Fecal Calprotectin is Able to Predict Clinical Relapse in Patients With Crohn's Disease in Remission After Infliximab Withdrawal. a Sub-Analysis of the Stori Study
Nicolas de Suray et al.
GASTROENTEROLOGY (2015)
Does Fecal Calprotectin Predict Short-Term Relapse After Stopping Tnfa-Blocking Agents In Inflammatory Bowel Disease Patients In Deep Remission?
Pauliina Molander et al.
JOURNAL OF CROHNS & COLITIS (2015)
Low Fecal Calprotectin Predicts Sustained Clinical Remission in Inflammatory Bowel Disease Patients: A Plea for Deep Remission
Erik Mooiweer et al.
JOURNAL OF CROHNS & COLITIS (2015)
Fecal calprotectin: towards a standardized use for inflammatory bowel disease management in routine practice
Edouard Louis
JOURNAL OF CROHNS & COLITIS (2015)
Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF alpha therapy: results from the COIN study
Mirthe Emilie van der Valk et al.
GUT (2014)
Targeted Peptide Measurements in Biology and Medicine: Best Practices for Mass Spectrometry- based Assay Development Using a Fit- for- Purpose Approach
Steven A. Carr et al.
MOLECULAR & CELLULAR PROTEOMICS (2014)
Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
Kavinderjit S. Nanda et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Infliximab Reduces Hospitalizations and Surgery Interventions in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Joao Costa et al.
INFLAMMATORY BOWEL DISEASES (2013)
When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel
Valerie Pittet et al.
JOURNAL OF CROHNS & COLITIS (2013)
Serum calprotectin as a biomarker for Crohn's disease
M.-A. Meuwis et al.
Journal of Crohns & Colitis (2013)
Risk of Melanoma and Nonmelanoma Skin Cancer Among Patients With Inflammatory Bowel Disease
Millie D. Long et al.
GASTROENTEROLOGY (2012)
Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped
Edouard Louis et al.
GASTROENTEROLOGY (2012)
Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions
Paola Picotti et al.
NATURE METHODS (2012)
Histidine-rich glycoprotein: the Swiss Army knife of mammalian plasma
Ivan K. H. Poon et al.
BLOOD (2011)
Crohn's Disease: an Immune Deficiency State
Daniel J. B. Marks et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2010)
Anti-TNF and Crohn's Disease: When Should We Stop?
Edouard Louis et al.
CURRENT DRUG TARGETS (2010)
Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data
K. Bodger et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Risk of Lymphoma Associated With Combination Anti-Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis
Corey A. Siegel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma
Terri A. Addona et al.
NATURE BIOTECHNOLOGY (2009)
Kringle 5 of human plasminogen, an angiogenesis inhibitor, induces both autophagy and apoptoltic death in endothelial cells
Tri Minh Bui Nguyen et al.
BLOOD (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Protein biomarker discovery and validation: the long and uncertain path to clinical utility
Nader Rifai et al.
NATURE BIOTECHNOLOGY (2006)
A simple biological score for predicting low risk of short-term relapse in Crohn's disease
Yann Consigny et al.
INFLAMMATORY BOWEL DISEASES (2006)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Share Paper
